Tag: Boston Scientific
REAL-PE demonstrates statistically significant lower major bleeding rates with Ekos system...
Data from the REAL-PE study were presented this week at TCT 2023 (23–26 October, San Francisco, USA) demonstrating that patients treated for pulmonary embolism...
Database analysis findings ‘matched precisely’ with reported reasons for venous stent...
A recent analysis recalled Venovo and Vici venous stents—initiated last year—characterized “significant differences” between reported device and patient issues, and subsequent interventions for the...
One-year results show ‘superior’ primary patency rate for Eluvia DES compared...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia...
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...
Boston Scientific and BD initiate venous stent recalls
Boston Scientific and BD have both initiated recalls of venous stents. According to a Food and Drug Administration (FDA) medical device recall notice posted...
Boston Scientific recalls Vici SDS and Vici RDS venous stent systems...
According to a medical device recall notice posted on the Food and Drug Administration (FDA) website, Boston Scientific has recalled its Vici venous stent...
Radiation exposure: ControlRad Select imaging system gains FDA market clearance
ControlRad has announced Food and Drug Administration (FDA) 510(k) clearance to market ControlRad Select, a technology that utilizes proprietary semi-transparent filters, a user-interface tablet,...